Henoch-Schonlein Purpura (IgA Vasculitis)

Henoch-Schönlein Purpura (IgA Vasculitis): A Comprehensive Medical Guide

1. Introduction & Overview

Henoch-Schönlein Purpura (HSP), now more commonly referred to as IgA Vasculitis (IgAV), is the most frequent form of systemic vasculitis in childhood. It is a small-vessel vasculitis characterized by deposition of immunoglobulin A (IgA)-containing immune complexes in the walls of small blood vessels, predominantly capillaries and venules. While most commonly diagnosed in children between the ages of 3 and 10 years, it can affect individuals of all ages. IgAV is a multisystemic disease, with its hallmark clinical manifestations typically involving the skin, joints, gastrointestinal tract, and kidneys. The etiology is often multifactorial, frequently triggered by antecedent infections, particularly upper respiratory tract infections. While generally a self-limiting condition, IgAV can lead to significant morbidity, especially if renal involvement is severe or prolonged. This guide aims to provide an exhaustive overview of IgAV, covering its definition, underlying mechanisms, clinical presentation, diagnostic approaches, and long-term outlook.

2. Technical Specifications & Mechanisms: Etiology and Pathophysiology

2.1 Etiology: The Triggers of IgA Vasculitis

The precise trigger for IgAV remains elusive in many cases, but a strong association with preceding infections is well-established.

• Infectious Triggers:
  • Bacterial Infections: Group A Streptococcus (GAS) is the most commonly implicated pathogen, particularly pharyngitis and scarlet fever. Other bacteria like Staphylococcus aureus, Helicobacter pylori, and Yersinia enterocolitica have also been linked.
  • Viral Infections: Infections with parvovirus B19, influenza virus, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) have been reported.
  • Other Infections: Fungal and parasitic infections are less commonly associated.
• Non-Infectious Triggers:
  • Medications: Certain drugs, including antibiotics (e.g., penicillin, cephalosporins), non-steroidal anti-inflammatory drugs (NSAIDs), and angiotensin-converting enzyme (ACE) inhibitors, have been anecdotally linked.
  • Allergens: Exposure to certain foods or environmental allergens can, in rare instances, precede the onset of IgAV.
  • Vaccinations: While rare and often temporally associated rather than causally linked, some vaccines have been implicated.

2.2 Pathophysiology: The Immune Complex Cascade

The central mechanism of IgAV involves the formation and deposition of IgA-containing immune complexes in the walls of small blood vessels, leading to a type of immune complex-mediated vasculitis.

• Immune Complex Formation:
  • An inciting event (e.g., infection) triggers an aberrant immune response, leading to increased production of IgA, particularly IgA1.
  • Aberrantly glycosylated IgA1, which has altered galactose residues in its hinge region, may be more prone to aggregation and immune complex formation.
  • These immune complexes, often containing IgA, IgA-immune complexes, and complement proteins (particularly C3), circulate in the bloodstream.
• Immune Complex Deposition:
  • These immune complexes preferentially deposit in the walls of small blood vessels, including capillaries, venules, and arterioles. The predilection for certain organs is thought to be related to vascular architecture and local immune responses.
• Inflammation and Vasculitis:
  • Upon deposition, these immune complexes activate the complement system and recruit inflammatory cells, such as neutrophils and macrophages.
  • This inflammatory cascade leads to damage of the vessel wall, characterized by endothelial cell activation, infiltration of inflammatory cells, and in severe cases, fibrinoid necrosis.
• Organ Involvement:
  • Skin: The deposition in dermal capillaries leads to palpable purpura, the hallmark of IgAV.
  • Joints: Inflammation in synovial vessels causes arthralgia and arthritis, typically migratory and affecting large joints.
  • Gastrointestinal Tract: Vasculitis in the intestinal wall can lead to edema, submucosal hemorrhage, and in severe cases, intussusception or perforation.
  • Kidneys: Glomerular deposition of IgA complexes triggers an inflammatory response in the glomeruli, leading to IgA nephropathy (also known as Berger's disease), which is the most significant determinant of long-term prognosis.

3. Clinical Manifestations & Presentation

IgAV typically presents with a constellation of symptoms affecting multiple organ systems. The classic tetrad of symptoms includes:

• Palpable Purpura: This is the most consistent and defining feature. It typically appears on the lower extremities, particularly the buttocks and extensor surfaces of the legs, often in a petechial or ecchymotic pattern. Unlike non-palpable purpura, these lesions are raised and can be felt upon palpation.
• Arthritis/Arthralgia: Joint pain and swelling are common, affecting approximately 75% of patients. It is usually migratory, affecting large joints such as the knees and ankles. Swelling can be significant, but joint effusions are typically serous, and permanent joint damage is rare.
• Abdominal Pain: Gastrointestinal involvement occurs in about 50-75% of patients and is characterized by colicky abdominal pain, often periumbilical. Other GI symptoms can include nausea, vomiting, diarrhea, and gastrointestinal bleeding (hematemesis or melena). Intussusception is a serious complication that can occur due to edema and hemorrhage in the intestinal wall.
• Renal Involvement (Nephritis): Renal manifestations occur in 25-50% of children and a higher proportion of adults. This can range from asymptomatic microscopic hematuria and proteinuria to more severe nephrotic or nephritic syndrome, and in rare cases, rapidly progressive glomerulonephritis.

3.1 Clinical Staging/Grading of IgA Vasculitis

While there isn't a universally adopted formal staging system for IgAV, clinical severity is often assessed based on the extent and severity of organ involvement. A common approach categorizes patients into:

• Mild: Limited to skin manifestations only.
• Moderate: Skin involvement with arthritis and/or mild GI symptoms.
• Severe: Significant GI bleeding, intussusception, or renal involvement requiring intervention.

Severity can also be graded based on renal pathology:

• Class I: Normal glomeruli on light microscopy.
• Class II: Mesangial cell proliferation and/or matrix increase.
• Class III: Mesangial proliferation with focal endocapillary proliferation and/or segmental necrosis.
• Class IV: Diffuse endocapillary proliferation and crescent formation.
• Class V: Global glomerulosclerosis and/or advanced crescent formation.

3.2 Standard Presentation Timeline

The onset of IgAV is often acute, following an antecedent infection by 1-3 weeks.

• Prodromal Phase: Many patients report a preceding upper respiratory tract infection (sore throat, cough).
• Acute Phase:
  • Skin: Purpura typically appears first, often within days of the prodrome.
  • Joints: Arthritis may develop concurrently with or shortly after the purpura.
  • GI: Abdominal pain and GI bleeding can manifest within days to weeks after the onset of purpura.
  • Kidneys: Renal involvement is usually the latest manifestation, often appearing 1-4 weeks after the initial symptoms, though it can be delayed or present from the outset.
• Resolution/Recurrence: In most cases, IgAV is self-limiting, with symptoms resolving within 1-4 weeks. However, relapses can occur, particularly in cases with significant renal involvement.

4. Differential Diagnosis

The diverse presentation of IgAV necessitates a broad differential diagnosis. Key considerations include:

5. Key Diagnostic Tests

The diagnosis of IgAV is primarily clinical, supported by laboratory and sometimes histopathological findings. The diagnostic criteria developed by the European League Against Rheumatism (EULAR)/Pediatric Rheumatology European Society (PReS) and the American College of Rheumatology (ACR) are widely used.

5.1 Clinical Diagnostic Criteria (EULAR/PReS 2010)

A diagnosis of IgAV is established if a patient presents with palpable purpura AND at least one of the following:

• Arthritis/Arthralgia:
• Abdominal Pain:
• Renal Involvement: (Proteinuria >0.5 g/day or Hematuria >5 RBCs/HPF)
• Histology: (Biopsy showing IgA deposition in small vessels)

5.2 Laboratory Investigations

• Complete Blood Count (CBC) with Differential:
  • Platelet Count: Usually normal, which helps differentiate from ITP.
  • White Blood Cell Count: May be elevated during acute inflammation, but typically normal.
  • Hemoglobin/Hematocrit: May be reduced in cases of significant GI bleeding.
• Inflammatory Markers:
  • Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Often elevated during active inflammation, but not specific for IgAV.
• Renal Function Tests:
  • Blood Urea Nitrogen (BUN) and Serum Creatinine: To assess kidney function.
  • Urinalysis: Essential for detecting proteinuria (dipstick or quantitative), hematuria (microscopic or macroscopic), and casts.
• Coagulation Profile:
  • Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT): Usually normal, helping to rule out coagulopathies.
• Serological Tests:
  • Antistreptolysin O (ASO) titer or Anti-DNase B titer: To confirm recent streptococcal infection, especially if pharyngitis was present.
  • IgA Levels: May be elevated in some patients, but not diagnostic.
  • Complement Levels (C3, C4): Usually normal in IgAV, which helps differentiate from other immune complex-mediated diseases like lupus.
• Stool Studies: If significant GI bleeding or diarrhea, to rule out infectious causes.

5.3 Histopathological Examination (Biopsy)

While not always required for diagnosis, a biopsy can confirm IgAV, especially in atypical cases or when differentiating from other vasculitides.

• Skin Biopsy:
  • Location: Purpuric lesion is ideal.
  • Findings: Leukocytoclastic vasculitis (inflammation of small vessels with neutrophil infiltration and nuclear debris) with IgA deposition in the vessel walls on immunofluorescence microscopy.
• Renal Biopsy:
  • Indication: Usually reserved for patients with significant or persistent renal involvement (e.g., nephrotic syndrome, impaired renal function, severe proteinuria/hematuria).
  • Findings: IgA nephropathy, characterized by mesangial IgA deposition on immunofluorescence, often accompanied by mesangial proliferation, endocapillary proliferation, and sometimes crescents on light microscopy.

5.4 Imaging Studies

• Abdominal Ultrasound: Can be useful for diagnosing complications like intussusception, detecting thickened bowel loops, and assessing for ascites.
• Plain Radiographs: May show signs of bowel obstruction or intussusception.

6. Long-Term Prognosis

The prognosis of IgAV is generally favorable, especially in children, with most cases resolving spontaneously within weeks to months. However, the long-term outlook is primarily determined by the presence and severity of renal involvement.

6.1 Renal Prognosis

• Mild Renal Involvement (isolated hematuria/proteinuria): The vast majority of these patients recover completely with no long-term sequelae.
• Moderate Renal Involvement (nephrotic or nephritic syndrome): Prognosis is more guarded. Approximately 10-25% of children and a higher percentage of adults may develop chronic kidney disease, end-stage renal disease (ESRD), or hypertension.
• Severe Renal Involvement (crescentic glomerulonephritis): This carries the worst prognosis, with a significant risk of progressive renal failure and ESRD.

Factors associated with poorer renal outcomes include:

• Age at onset: Older age at diagnosis is associated with a higher risk of renal sequelae.
• Severity of initial renal presentation: Nephrotic syndrome, significant proteinuria (>1 g/day), and impaired renal function at diagnosis are poor prognostic indicators.
• Histological findings on renal biopsy: The presence of crescents (Class IV and V IgA nephropathy) is a strong predictor of progressive renal disease.
• Persistence of renal symptoms: Prolonged hematuria or proteinuria beyond 6 months.
• Adult onset: Adults tend to have more severe disease and a higher risk of renal complications.

6.2 Other Organ Involvement Prognosis

• Skin: Typically resolves without sequelae. Recurrent purpura can occur but is usually self-limiting.
• Joints: Arthritis resolves without permanent joint damage in almost all cases.
• Gastrointestinal Tract: Most GI symptoms resolve spontaneously. Complications like intussusception require prompt management, but recovery is usually complete. However, rare cases of intestinal perforation can lead to significant morbidity.

6.3 Recurrence

Recurrences of IgAV can happen, particularly in patients with initial severe disease or ongoing renal involvement. These relapses are typically milder than the initial presentation.

7. Management of IgA Vasculitis

Management is primarily supportive and focuses on symptomatic relief and preventing complications.

• Supportive Care:
  • Rest: Especially during the acute phase.
  • Hydration: Crucial, particularly with fever or GI losses.
• Pain Management:
  • NSAIDs: Can be used for arthritis pain, but with caution in patients with significant renal involvement.
  • Acetaminophen: A safer alternative for pain relief.
• Gastrointestinal Symptoms:
  • Antiemetics: For nausea and vomiting.
  • Proton Pump Inhibitors (PPIs): May be used for GI bleeding or to protect the gastric mucosa.
• Renal Involvement:
  • Mild: Close monitoring of urinalysis and renal function.
  • Moderate to Severe:
    • Corticosteroids: Prednisolone (1 mg/kg/day, max 60 mg/day) is often used, especially for severe GI symptoms or significant renal involvement. The dose is usually tapered over several weeks.
    • Immunosuppressants: In cases of severe or refractory renal disease (e.g., crescentic glomerulonephritis), other immunosuppressants like azathioprine, mycophenolate mofetil, or cyclophosphamide may be considered, often in conjunction with corticosteroids.
    • ACE Inhibitors/Angiotensin Receptor Blockers (ARBs): May be used to help manage proteinuria and hypertension in patients with renal involvement.
• Management of Complications:
  • Intussusception: Requires prompt reduction, often with air or saline enema, or surgical intervention if reduction fails.

8. Frequently Asked Questions (FAQ)

8.1 What is Henoch-Schönlein Purpura (IgA Vasculitis)?

Henoch-Schönlein Purpura (HSP), now more commonly known as IgA Vasculitis (IgAV), is an inflammatory condition that causes small blood vessels in the skin, joints, intestines, and kidneys to become inflamed. It is the most common form of vasculitis in children.

8.2 What causes IgA Vasculitis?

The exact cause is unknown, but it is often triggered by an infection, most commonly a viral or bacterial infection of the upper respiratory tract, such as a sore throat. Other triggers like medications or allergens are less common.

8.3 What are the main symptoms of IgA Vasculitis?

The classic symptoms include a rash of palpable purpura (raised, bruise-like spots) typically on the legs and buttocks, joint pain and swelling (arthritis), abdominal pain, and sometimes blood in the urine or stool.

8.4 How is IgA Vasculitis diagnosed?

Diagnosis is primarily based on clinical symptoms. A doctor will look for palpable purpura along with at least one of the other characteristic symptoms (arthritis, abdominal pain, or kidney involvement). Blood tests, urine tests, and sometimes a skin or kidney biopsy may be used to support the diagnosis and assess severity.

8.5 Is IgA Vasculitis contagious?

No, IgA Vasculitis itself is not contagious. However, the infections that can trigger it, like strep throat, are contagious.

8.6 How is IgA Vasculitis treated?

Treatment is mainly supportive, focusing on managing symptoms and preventing complications. This includes rest, pain relief for joint pain, and sometimes medications like corticosteroids for severe symptoms or kidney involvement.

8.7 What is the long-term outlook for children with IgA Vasculitis?

Most children recover fully within a few weeks to months without long-term problems. However, a small percentage can develop kidney problems that may persist.

8.8 What are the risks for adults with IgA Vasculitis?

Adults tend to have more severe disease and a higher risk of developing significant kidney problems compared to children.

8.9 Can IgA Vasculitis come back?

Yes, relapses can occur, especially in individuals with more severe initial disease or ongoing kidney involvement. However, these are often milder than the first episode.

8.10 When should I seek medical attention for suspected IgA Vasculitis?

You should seek medical attention if you or your child develops a rash of palpable purpura, especially if accompanied by joint pain, abdominal pain, or changes in urination. Prompt evaluation is important, particularly to assess for and manage potential kidney involvement.

8.11 What is the role of IgA in IgA Vasculitis?

IgA is a type of antibody. In IgAV, abnormal IgA antibodies form immune complexes that deposit in blood vessel walls, triggering inflammation and damage.

8.12 Can IgA Vasculitis affect other organs besides the skin, joints, GI tract, and kidneys?

While these are the most common sites, IgAV can rarely affect other organs, including the lungs, heart, and nervous system. However, this is uncommon.

8.13 What is the difference between Henoch-Schönlein Purpura and IgA Vasculitis?

Henoch-Schönlein Purpura (HSP) is the older, historical name for the condition. The term IgA Vasculitis (IgAV) is now preferred by many medical professionals as it more accurately describes the underlying pathology – a vasculitis driven by IgA immune deposits.

8.14 How is kidney involvement monitored in IgA Vasculitis?

Kidney involvement is monitored through regular urinalysis to check for protein and blood, and blood tests to assess kidney function (e.g., creatinine, BUN).

8.15 Are there any specific dietary recommendations for IgA Vasculitis?

There are no specific dietary recommendations that are proven to treat IgAV. A balanced diet is generally recommended. Some individuals may find that certain foods trigger or worsen their symptoms, but this is not a universal finding.

8.16 What is the prognosis for IgA Vasculitis with severe kidney disease?

Severe kidney disease, especially if it involves crescent formation on biopsy, carries a less favorable prognosis and a higher risk of developing chronic kidney disease or requiring dialysis. Early and aggressive management is crucial in these cases.

This comprehensive guide provides an in-depth understanding of IgA Vasculitis, equipping healthcare professionals with the knowledge to diagnose, manage, and counsel patients effectively.
=== CONTENT ===

Related Clinical Integration

In the clinical management of Henoch-Schonlein Purpura (IgA Vasculitis), a multidisciplinary approach is essential for monitoring systemic involvement and alleviating patient discomfort. Given the risk of renal involvement, clinicians should prioritize Kidney function tests (e.g., serum creatinine, BUN, urinalysis) / اختبارات وظائف الكلى (3095) (خدمات رعاية عامة) to assess for glomerulonephritis, while atypical presentations may necessitate a Skin Biopsy for Nerve Fiber Density / خزعة الجلد لتحديد كثافة الألياف العصبية (عملية صغرى في العيادة) performed with a Biopsy punch / مبزل الخزعة to confirm the diagnosis via direct immunofluorescence. Symptomatic relief for arthralgia and abdominal pain is typically managed with analgesics such as Acetaminophen-Codeine / أسيتامينوفين-كوديين 300mg / 30mg, whereas severe inflammatory manifestations may require targeted corticosteroid therapy, such as Depo-Medrol / ديبو-ميدرول 80 mg, to mitigate systemic vasculitic damage.